Market Capitalization (Millions $) |
2 |
Shares
Outstanding (Millions) |
1 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
9 |
Cash Flow (TTM) (Millions $) |
-7 |
Capital Exp. (TTM) (Millions $) |
1 |
Biondvax Pharmaceuticals Ltd
Biondvax Pharmaceuticals Ltd is a biopharmaceutical company that focuses on the development and commercialization of advanced vaccines against infectious diseases. The company utilizes its proprietary technology platform, known as the Universal Flu Vaccine, to create vaccines that offer broader protection against multiple strains of influenza.
Biondvax's Universal Flu Vaccine is designed to provide long-lasting immunity and is also effective against future variants of influenza, including seasonal and pandemic strains. The vaccine is based on conserved epitopes, which are parts of the virus that do not mutate easily, making it a promising solution for combating influenza.
In addition to its Universal Flu Vaccine, Biondvax is also involved in the development of other vaccine candidates for diseases such as SARS-CoV-2 (COVID-19) and malaria. The company collaborates with research institutions, pharmaceutical companies, and governmental bodies to support the advancement of its products.
Biondvax is committed to addressing global health challenges and improving vaccination strategies through its innovative vaccine technologies. The company's goal is to contribute to the prevention and control of infectious diseases, ultimately benefiting public health worldwide.
Company Address: Jerusalem BioPark Jerusalem 0
Company Phone Number: 8-930-2529 Stock Exchange / Ticker: NASDAQ BVXV
BVXV is expected to report next financial results on April 16, 2024. |
|
|